© 2018 Miraculo Inc. All Rights Reserved
Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity
Cannabinoids are a collection of naturally occurring compounds that are situated in the marijuana plant (cannabis sativa). Cannabidiol (CBD) is the main chemical within the cannabis plant and it is said by the wide scientific community that it has anti inflammatory effects when induced into animal cells. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said to have a psychotropic effect. Cannabinoid receptors (CB1 and CB2) are located in the endocannabinoid system and gives cannabinoids power to bind and thrive in the body. This paper will look at how endocannabinoids modulate the frequency and severity of seizure.
Cannabinoids have anti seizure properties
The anticonvulsant impact of cannabinoids has demonstrated to be controlled through the triggering of the cannabinoid CB1 receptor. This experiment was conducted to review the impacts of endocannabinoids on seizure frequency and severity. The anticonvulsant impact of endocannabinoids, was reviewed in this seizure model using male mice and was discovered to be a great anticonvulsant. The metabolically efficient endocannabinoid was also seen to be a strong anticonvulsant in this model. More so, treatment with the cannabinoid CB1 receptor selective antagonist completely destroyed the anticonvulsant impact of endocannabinoids as well as, showing a cannabinoid CB1 receptor-mediated anticonvulsant action for both endocannabinoid chemical compounds. More so, the influence of cannabinoid CB1 receptor agonist on seizure severity was reviewed using synthetic cannabinoids. These results show that synthetic cannabinoids massively decrease seizure severity compared to animals, suggesting the presence of an endocannabinoids changing seizure activity. These results illustrate that endocannabinoids have anticonvulsant properties in animals and further suggest that the cannabinoid CB1 receptor is a major endogenous target of seizure modulation.
Cannabinoids can be therapeutic to people with epilepsy
Cannabinoids have been seen to be therapeutic in the treatment of epilepsy by reducing seizure severity without side effects. This study demonstrates that cannabinoids physiological properties can change the size of the seizure and its duration. More so, these results suggest that the CB1 receptor can the endocannabinoid system are potential go to places when treating and controlling epilepsy. This study provides direct evidence for a physiological role of endocannabinoids in modulating seizure threshold and severity. In addition, these data further establish the cannabinoid CB1 receptor and the endogenous cannabinoid system as a potential treatment target for the control of epilepsy. More studies are needed to investigate the role of this system.Evidence-for-a-physiological-role-of-endocannabinoids-in-the-modulation-of-seizure-threshold-and-severity